SHR-A1403, a novel c-Met antibody-drug conjugate, exerts encouraging anti-tumor activity in c-Met-overexpressing models

Recent advances in the discovery of small molecule c-Met Kinase inhibitors

(2018) Palak K. Parikh et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Fate of Antibody-Drug Conjugates in Cancer Cells

(2018) Cécile Chalouni et al.   JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

Function of the c-Met receptor tyrosine kinase in carcinogenesis and associated therapeutic opportunities

(2018) Yazhuo Zhang et al.   Molecular Cancer

Using PDX for Preclinical Cancer Drug Discovery: The Evolving Field

(2018) Juliet Williams   Journal of Clinical Medicine

Tivantinib for the treatment of hepatocellular carcinoma

(2017) Jan Best et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phase II study of the antibody-drug conjugate TAK-264 (MLN0264) in patients with metastatic or recurrent adenocarcinoma of the stomach or gastroesophageal junction expressing guanylyl cyclase C

(2017) Khaldoun Almhanna et al.   INVESTIGATIONAL NEW DRUGS

C-Met as a potential target for the treatment of gastrointestinal cancer: Current status and future perspectives

(2017) Afsane Bahrami et al.   JOURNAL OF CELLULAR PHYSIOLOGY

Current status and perspectives of patient-derived xenograft models in cancer research

(2017) Yunxin Lai et al.   Journal of Hematology & Oncology

A comprehensive analysis of clinical outcomes in lung cancer patients harboring a MET exon 14 skipping mutation compared to other driver mutations in an East Asian population

(2017) Chien-Hung Gow et al.   LUNG CANCER

Intracellular trafficking of new anticancer therapeutics: antibody–drug conjugates

(2017) Muhammad Kalim et al.   Drug Design Development and Therapy

Phase I study of safety and pharmacokinetics of the anti-MUC16 antibody–drug conjugate DMUC5754A in patients with platinum-resistant ovarian cancer or unresectable pancreatic cancer

(2016) J. F. Liu et al.   ANNALS OF ONCOLOGY

Anti-c-Met monoclonal antibody ABT-700 breaks oncogene addiction in tumors with MET amplification

(2016) Jieyi Wang et al.   BMC CANCER

ABBV-399, a c-Met Antibody–Drug Conjugate that Targets Both MET –Amplified and c-Met–Overexpressing Tumors, Irrespective of MET Pathway Dependence

(2016) Jieyi Wang et al.   CLINICAL CANCER RESEARCH

MINI01.03: Phase (Ph) I Study of the Safety and Efficacy of the cMET Inhibitor Capmatinib (INC280) in Patients with Advanced cMET+ NSCLC

(2016) Todd M. Bauer et al.   Journal of Thoracic Oncology

Phase I Study of DMOT4039A, an Antibody-Drug Conjugate Targeting Mesothelin, in Patients with Unresectable Pancreatic or Platinum-Resistant Ovarian Cancer

(2016) C. D. Weekes et al.   MOLECULAR CANCER THERAPEUTICS

Internalization, Trafficking, Intracellular Processing and Actions of Antibody-Drug Conjugates

(2015) Shi Xu   PHARMACEUTICAL RESEARCH

Volitinib, a potent and highly selective c-Met inhibitor, effectively blocks c-Met signaling and growth in c-MET amplified gastric cancer patient-derived tumor xenograft models

(2014) Paul R. Gavine et al.   Molecular Oncology

Genentech to salvage anti-MET antibody with subgroup analysis

(2014) Cormac Sheridan   NATURE BIOTECHNOLOGY

MET inhibitors start on road to recovery

(2014) Ken Garber   NATURE REVIEWS DRUG DISCOVERY

Agonist monoclonal antibodies against HGF receptor protect cardiac muscle cells from apoptosis

(2010) Stefano Pietronave et al.   AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY

MetMAb, the One-Armed 5D5 Anti-c-Met Antibody, Inhibits Orthotopic Pancreatic Tumor Growth and Improves Survival

(2008) H. Jin et al.   CANCER RESEARCH